Literature DB >> 6682490

Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives.

D R Brown, M J Robertson, L I Goldberg.   

Abstract

The effects of the pure narcotic antagonists, naloxone and naltrexone, and their quaternary derivatives, methylnaloxone and methylnaltrexone, were examined in reversing the catalepsy induced by morphine in rats. Morphine, 20 mg/kg, induced rigid catalepsy which attained a peak effect (as manifested by duration of catalepsy) at 60-120 min and progressively declined thereafter. Both naloxone and naltrexone, administered subcutaneously 40 min after the injection of morphine, dose-dependently reduced the duration of the catalepsy at doses of 10-30 micrograms/kg. Methylnaloxone also completely reversed the catalepsy at doses of 1-10 mg/kg, when given subcutaneously. In contrast, the subcutaneous administration of methylnaltrexone only partially reversed the catalepsy at doses up to 56 mg/kg 60-90 min post-morphine. The extent of the reversal of catalepsy produced by methylnaltrexone tended to increase with time. Methylnaltrexone, administered into the cerebral ventricles 70 min after the injection of morphine, completely suppressed the catalepsy with an ED50 of approx. 1 microgram/kg when tested at 90 min after morphine. These results indicate that opiate-induced catalepsy is predominantly mediated at sites within the central nervous system. Methylnaltrexone is about 10,000 times more potent in reversing catalepsy when administered centrally than when administered peripherally. Thus, methylnaltrexone may be useful in defining sites of opiate action and in therapeutically blocking undesirable peripheral effects of opiate analgesics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682490     DOI: 10.1016/0028-3908(83)90246-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  micro-Opioid receptor activation prevents acute hepatic inflammation and cell death.

Authors:  Dania Chakass; David Philippe; Edmone Erdual; Sébastien Dharancy; Mathilde Malapel; Caroline Dubuquoy; Xavier Thuru; Jerome Gay; Claire Gaveriaux-Ruff; Pierre Dubus; Philippe Mathurin; Brigitte L Kieffer; Pierre Desreumaux; Mathias Chamaillard
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

2.  Suppression of deprivation-induced water intake in the rat by opioid antagonists: central sites of action.

Authors:  M Ukai; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Characterization of the discriminative stimulus effects of centrally administered morphine in the rat.

Authors:  K W Locke; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Quaternary naloxone enhances acquisition of a discriminated Y-maze escape and a one-way active avoidance task in mice.

Authors:  J L Martinez; J S de Graaf
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

5.  Ethanol-induced social facilitation in adolescent rats: role of endogenous activity at mu opioid receptors.

Authors:  Elena I Varlinskaya; Linda P Spear
Journal:  Alcohol Clin Exp Res       Date:  2009-03-19       Impact factor: 3.455

6.  Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice.

Authors:  D Matthew Walentiny; Essie Komla; Léa T Moisa; Mohammed A Mustafa; Justin L Poklis; Hamid I Akbarali; Patrick M Beardsley
Journal:  Neuropharmacology       Date:  2020-12-11       Impact factor: 5.250

7.  Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation.

Authors:  Eike Floettmann; Khanh Bui; Mark Sostek; Kemal Payza; Michael Eldon
Journal:  J Pharmacol Exp Ther       Date:  2017-03-23       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.